non alcoholic fatty liver disease. Other specified inflammatory liver diseases
Conditions
Interventions
Intervention 1: intervention group:2 gram citrulline per day for three months. Intervention 2: placebo group:2 gram starche per day for three months.
Treatment - Other
intervention group:2 gram citrulline per day for three months
placebo group:2 gram starche per day for three months
Sponsors
Shahid Beheshti University of Medical Sciences, National Nutrition and Food Technology Research
Colorectal Research Center,IRAN University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria for the study: Age 18 and older;Concentrations of liver enzymes ALT and AST greater than 1.5 times normal;Evidence of nonalcoholic steatohepatitis in Fibroscan (Controlled Attenuation Parameter (CAP) score> 263);Have not a history of consumption alcohol more than 10 milligrams of per day for women and more than 20 mg per day for men;Not consume any dietary supplement in the past three months not consume any hepatotoxic drugs such as phenytoin, lithium Exclusion criteria: Not continue to cooperation;Biliary diseases; autoimmune and cancer and inherited disorders affecting liver during the study;Those less than 10% supplemen at the end of the sixth and twelth week consume.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-C. Timepoint: Being andend of intervention. Method of measurement: Enzymatic methods using kits.;HDL-C. Timepoint: Being andend of intervention. Method of measurement: Enzymatic methods using kits.;TG. Timepoint: Being andend of intervention. Method of measurement: Enzymatic methods using kits.;Total Cholesterol. Timepoint: Being andend of intervention. Method of measurement: Enzymatic methods using kits.;FBS. Timepoint: Being andend of intervention. Method of measurement: Enzymatic methods using kits.;Fasting insulin. Timepoint: Being andend of intervention. Method of measurement: Radioimmunoassay µU/mL.;AST. Timepoint: Being andend of intervention. Method of measurement: Enzymatic methods using kits.;ALT. Timepoint: Being andend of intervention. Method of measurement: Enzymatic methods using kits µg/m.;HOMA. Timepoint: Being andend of intervention. Method of measurement: Calculation.;TNF-a. Timepoint: Being andend of intervention. Method of measurement: Elisa Pg/dl.;IL_6. Timepoint: Being andend of intervention. Method of measurement: Elisa Pg/dl.;Steatosis. Timepoint: Being andend of intervention. Method of measurement: Ultrasonography Grade 0: absence of steatosis grade 1: mild steatosis grade 2: moderate steatosis grade 3: severe steatosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total energy intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire Kcal per day.;Carbohydrate intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire gram per day.;Protein intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire gram per day.;Total fat intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire gram per day.;SAFA intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire gram per day.;PUFA intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire gram per day.;MUFA intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire gram per day.;Total fiber intake. Timepoint: Beginning and end of intervention. Method of measurement: questionnaire gram per day. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzita Hekmatdoust
National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sci
Outcome results
None listed